• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

RealTalk MS

  • Home
  • Past Episodes
  • Videos
  • About RealTalk MS
  • Press Kit
  • Contact Us

Main Content

Photo courtesy of National MS Society

RealTalk MS Is On Right Now!

Join host Jon Strum each week as he breaks down the latest multiple sclerosis news. We’re talking about the amazing MS research that’s taking place in laboratories around the world — and we’re talking to some of the brilliant neuroscientists who are conducting that research!

We’re monitoring the debate among our lawmakers surrounding prescription drug price transparency, healthcare legislation, funding for new and experimental MS research — anything that might impact your MS treatments.

And we’re talking with MS activists, MS caregivers, MS fundraisers, and other heroes who strive to raise the bar for those who battle MS every day.

If you’re affected by multiple sclerosis — as a patient, caregiver, family member, or friend — join us for RealTalk MS.

Episode 440: An MS Specialist Responds to the FDA with Dr. William Conte


This past December, the FDA issued a Complete Response Letter to drug manufacturer Sanofi in response to Sanofi's application seeking approval for Tolebrutinib, the first in a new category of investigational disease-modifying therapies to undergo FDA review.

A Complete Response Letter is an official letter from the FDA to a drug manufacturer stating that the agency can't approve a new medicine in its current form. It's not an outright “no” that kills a project; it's more like a “not yet.” However, this Complete Response Letter raised some issues which, at first glance, don't appear to be easily fixable.

Dr. William Conte

Sanofi has pointed out that the issues raised in the Complete Response Letter were markedly different from the guidance they received from the FDA over the course of this approval process. Sanofi has also indicated that it would work with the FDA to find a path forward for Tolebrutinib.

Dr. William Conte, an MS Specialist and a principal investigator in the Phase 3 clinical trial for Tolebrutinib, has published an article responding to the FDA's Complete Response Letter. This week, Dr. Conte joins me to discuss the FDA's action and his response to that action.

We have a lot to talk about! Are you ready for RealTalk MS??!


This Week: We're at the 2026 ACTRIMS Forum  :22

Check out the official ACTRIMS Forum Insider podcast!  :42

The FDA's Complete Response Letter about Tolebrutinib  1:09

Dr. William Conte responds to the FDA's Complete Response Letter  4:09

Share this episode  38:10

Next week's episode  38:30


SHARE THIS EPISODE OF REALTALK MS

Just copy this link & paste it into your text or email: https://realtalkms.com/440

ADD YOUR VOICE TO THE CONVERSATION

I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts!

Email: jon@realtalkms.com
Phone: (310) 526-2283

And don't forget to join us in the RealTalk MS Facebook group!


LINKS

If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com

Support Jon at WALK MS
https://realtalkms.com/walkms

Find out about ABLEnow Accounts
https://ablenow.com

JOIN: The RealTalk MS Facebook Group
https://facebook.com/groups/realtalkms

REVIEW: Give RealTalk MS a rating and review
http://www.realtalkms.com/review


Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com.

RealTalk MS Episode 440
Guests: Dr. William Conte

Privacy Policy

 

Primary Sidebar

ARE YOU ON OUR MAILING LIST?

Sign up to receive email updates from RealTalk MS. You’ll get a personal advance heads-up about every upcoming podcast episode.

And P.S. — We promise to keep your private information private! We won’t sell it, trade it, or share it.

Connect With Us

  • Email
  • Facebook
  • Instagram
  • LinkedIn
  • RSS
  • Twitter
  • YouTube

Copyright © 2026 RealTalk MS